GAinS (Genomic Advances in Sepsis)

Date Opened: 2005
Type:
Size: Multi-centre
Current Status: Open
Recruitment to date:  55

Lead Researchers (UK): 
Prof Charles Hinds (Intensive Care Unit, St. Bartholomew’s Hospital, London), Dr Chris Garrard (Intensive Care Unit, John Radcliffe Hospital, Oxford)
Principle Investigator (Queen Elizabeth Hospital Birmingham): Dr Julian Bion (Intensive Care Unit, Queen Elizabeth University Hospital, Birmingham)


Overview

Sepsis is the systemic inflammatory response to infection and is the most common cause of death in adult intensive care units.

There are up to 750,000 cases of severe sepsis per year in the USA and around 21,000 in the UK, where it accounts for approximately 46% of all bed days in intensive care units. Mortality rates worldwide could be as high as 1,400 per day.

Sepsis has a huge impact on healthcare expenditure and resources with annual costs to hospitals in Europe of around €7.6 billion.

Early diagnosis and treatment may improve the overall outcomes of many of these patients and the GAinS study is a multi-centre, UK-based study which aims to understand how and why patients react to certain infections through genetic analysis.

 

Who is eligible

Any adult admitted to intensive care and diagnosed with sepsis is eligible to take part in this study.

 

The Trial

Blood and urine samples will be taken on four separate occasions which will be used to determine which genes are active and which chemicals are released in sepsis.

Researchers will look at the genetic predisposition to the onset, progression and severity of infections.

Better understanding could lead to better care for patients though improved treatments that are tailored and targeted to each individual.

 

Measuring Success

The proposed data collection is designed to enable us to identify with confidence genomic influences on:
1. The susceptibility of patients with predisposing infectious diseases to the development of severe sepsis/septic shock and specific organ failures.
2. The outcome from sepsis/severe sepsis/septic shock in these patients.
3. The outcome from specific organ failures in these patients.